Equities

Simcere Pharmaceutical Group Ltd

Simcere Pharmaceutical Group Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)6.61
  • Today's Change-0.17 / -2.51%
  • Shares traded3.31m
  • 1 Year change-12.22%
  • Beta0.4365
Data delayed at least 15 minutes, as of Nov 22 2024 08:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments2,0182,6232,183
Total Receivables, Net2,6952,3792,436
Total Inventory615305235
Prepaid expenses1566756
Other current assets, total1558669
Total current assets5,6395,4584,980
Property, plant & equipment, net2,1702,1391,931
Goodwill, net142173173
Intangibles, net71638060
Long term investments1,5802,2152,651
Note receivable - long term1000--
Other long term assets------
Total assets10,85410,78910,161
LIABILITIES
Accounts payable317335324
Accrued expenses------
Notes payable/short-term debt7621,184992
Current portion long-term debt/capital leases333167570
Other current liabilities, total1,2741,2801,178
Total current liabilities2,6862,9673,064
Total long term debt33415674
Total debt1,4291,5071,636
Deferred income tax103115143
Minority interest01626
Other liabilities, total508403418
Total liabilities3,6313,6573,724
SHAREHOLDERS EQUITY
Common stock3,1743,0813,003
Additional paid-in capital------
Retained earnings (accumulated deficit)3,9354,0143,418
Treasury stock - common------
Unrealized gain (loss)12(19)137
Other equity, total10256(121)
Total equity7,2237,1326,437
Total liabilities & shareholders' equity10,85410,78910,161
Total common shares outstanding2,6172,6282,628
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.